Notice of Termination of Equity Distribution Agreement between Hemispherx Biopharma, Inc. and Chardan Capital Markets, LLC

Summary

Hemispherx Biopharma, Inc. has notified Chardan Capital Markets, LLC that it is terminating their Equity Distribution Agreement, originally dated December 15, 2015. The termination is effective immediately as of December 11, 2018, with Chardan waiving the usual ten-day notice period. This letter serves as formal notice of the agreement's end and confirms mutual consent to the immediate termination.

EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

 

December 11, 2018

 

Via facsimile 646 ###-###-####

 

Mr. George Santana

Managing Director, Investment Banking

Chardan Capital Markets, LLC

17 State Street, Suite 1600

New York, NY 10004

 

  Re: Notice of termination of Equity Distribution Agreement

 

Dear George:

 

Pursuant to Section 11(b) of the Equity Distribution Agreement by and between Chardan Capital Markets, LLC (“Chardan”) and Hemispherx Biopharma, Inc. (the “Company”) dated December 15, 2015 (the “EDA”), the Company hereby notifies Chardan that it is terminating the EDA effective December 11, 2018, and Chardan has waived the contract ten (10) day notice.

 

  Sincerely,
   
  /s/ Thomas K Equels
  Thomas K. Equels, CEO

 

cc: Anthony J. Marsico, Esq.
  Mintz Levin Cohn Ferris Glovsky and Popeo PC
  Chrysler Center
  666 Third Avenue
  New York, NY 10017

 

Corporate Headquarters
2117 SW Highway 484, Ocala FL 34473   t: 407 ###-###-#### f: 407 ###-###-####
Finance & Administration      
600 Main Street, Suite 2, Riverton NJ 08077   t: 215 ###-###-#### f: 215 ###-###-####
Manufacturing      
783 Jersey Ave, New Brunswick, NJ 08901 www.hemispherx.net t: 732 ###-###-#### f: 732 ###-###-####